Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Rabies Overview | 9 | 1 |
| Therapeutics Development | 10 | 2 |
| Pipeline Products for Rabies Overview | 10 | 1 |
| Pipeline Products for Rabies Comparative Analysis | 11 | 1 |
| Rabies Therapeutics under Development by Companies | 12 | 2 |
| Rabies Therapeutics under Investigation by Universities/Institutes | 14 | 1 |
| Rabies Pipeline Products Glance | 15 | 4 |
| Late Stage Products | 15 | 1 |
| Clinical Stage Products | 16 | 1 |
| Early Stage Products | 17 | 1 |
| Unknown Stage Products | 18 | 1 |
| Rabies Products under Development by Companies | 19 | 1 |
| Rabies Products under Investigation by Universities/Institutes | 20 | 1 |
| Rabies Companies Involved in Therapeutics Development | 21 | 20 |
| Beijing Minhai Biotechnology Co., Ltd | 21 | 1 |
| BioClonetics Immunotherapeutics, Inc. | 22 | 1 |
| Celltrion, Inc. | 23 | 1 |
| Curevac AG | 24 | 1 |
| Humabs BioMed SA | 25 | 1 |
| Indian Immunologicals Limited | 26 | 1 |
| Kaketsuken K.K. | 27 | 1 |
| Kamada Ltd. | 28 | 1 |
| Molecular Targeting Technologies, Inc. | 29 | 1 |
| NanoViricides, Inc. | 30 | 1 |
| Novavax, Inc. | 31 | 1 |
| PaxVax, Inc. | 32 | 1 |
| Prosetta Biosciences, Inc. | 33 | 1 |
| Sanofi Pasteur SA | 34 | 1 |
| Serum Institute of India Limited | 35 | 1 |
| Sinovac Biotech Ltd. | 36 | 1 |
| Synermore Biologics Co Ltd | 37 | 1 |
| Trellis Bioscience, Inc. | 38 | 1 |
| VBI Vaccines Inc | 39 | 1 |
| Zydus Cadila Healthcare Limited | 40 | 1 |
| Rabies Therapeutics Assessment | 41 | 9 |
| Assessment by Monotherapy Products | 41 | 1 |
| Assessment by Combination Products | 42 | 1 |
| Assessment by Target | 43 | 2 |
| Assessment by Mechanism of Action | 45 | 1 |
| Assessment by Route of Administration | 46 | 2 |
| Assessment by Molecule Type | 48 | 2 |
| Drug Profiles | 50 | 33 |
| (Ebola [Zaire] + rabies) (bivalent) vaccine Drug Profile | 50 | 1 |
| CTP-19 Drug Profile | 51 | 1 |
| CV-8102 Drug Profile | 52 | 1 |
| IMT-504 Drug Profile | 53 | 2 |
| KD-357 Drug Profile | 55 | 1 |
| MAb-3 Drug Profile | 56 | 1 |
| Monoclonal Antibodies for Rabies Drug Profile | 57 | 1 |
| Monoclonal Antibodies for Rabies Drug Profile | 58 | 1 |
| Monoclonal Antibodies to Inhibit Glycoprotein for Rabies Drug Profile | 59 | 1 |
| Monoclonal Antibody for Rabies Drug Profile | 60 | 1 |
| nadorameran Drug Profile | 61 | 1 |
| PAV-866 Drug Profile | 62 | 1 |
| RabiCide-I Drug Profile | 63 | 2 |
| rabies [strain Wistar PM/WI 38-1503-3M] vaccine Drug Profile | 65 | 1 |
| rabies immune globulin (human) Drug Profile | 66 | 1 |
| rabies vaccine Drug Profile | 67 | 1 |
| rabies vaccine Drug Profile | 68 | 1 |
| rabies vaccine Drug Profile | 69 | 1 |
| rabies vaccine Drug Profile | 70 | 1 |
| rabies vaccine Drug Profile | 71 | 1 |
| rabies vaccine Drug Profile | 72 | 1 |
| rabies vaccine Drug Profile | 73 | 1 |
| rabies vaccine Drug Profile | 74 | 1 |
| rabies vaccine 1 Drug Profile | 75 | 1 |
| Rabimabs Drug Profile | 76 | 1 |
| RVC-20 Drug Profile | 77 | 1 |
| RVC-58 Drug Profile | 78 | 1 |
| SII RMab Drug Profile | 79 | 1 |
| SO-57 Drug Profile | 80 | 1 |
| SOJB Drug Profile | 81 | 1 |
| SYN-023 Drug Profile | 82 | 1 |
| Rabies Dormant Projects | 83 | 1 |
| Rabies Product Development Milestones | 84 | 7 |
| Featured News &Press Releases | 84 | 1 |
| Sep 01, 2016: Kamada and Kedrion Seek FDA Approval of Human Rabies Immunoglobulin as a Post-Exposure Treatment | 84 | 1 |
| Jan 04, 2016: Yisheng Biopharma Announces Positive Results of Phase I Clinical Trial of a Novel Rabies Vaccine with PIKA Adjuvant | 84 | 2 |
| Dec 23, 2015: Kamada's Human Rabies Immune Globulin Successfully Meets Primary Endpoint in U.S. Pivotal Phase 2/3 Clinical Trial as a Post-Exposure Treatment | 86 | 1 |
| Mar 23, 2015: Yisheng Biopharma develops new therapeutic vaccine for rabies | 87 | 1 |
| Mar 04, 2014: Kamada Completes Enrollment in U.S. Pivotal Clinical Trial with KamRAB as a Post-Exposure Treatment for Rabies | 88 | 1 |
| Aug 28, 2009: Rabies Vaccine Supply Update: IMOVAX Rabies Vaccine Availability | 88 | 1 |
| Jul 15, 2008: Kamada Gains Approval of KamRAB in Israel | 89 | 1 |
| Oct 23, 2007: Kamada Awarded Another Contract To Deliver Its KamRAB Anti-rabies Vaccination To Latin America | 89 | 1 |
| May 01, 2007: Kamada Obtains FDA Approval to Commence Phase II and III Clinical Trials For Its KamRAB Anti-rabies Passive Immunization Product | 90 | 1 |
| Sep 18, 2003: Molecular Targeting Technologies, Inc. Forms Partnership With North China Pharmaceutical Company | 90 | 1 |
| Appendix | 91 | 2 |
| Methodology | 91 | 1 |
| Coverage | 91 | 1 |
| Secondary Research | 91 | 1 |
| Primary Research | 91 | 1 |
| Expert Panel Validation | 91 | 1 |
| Contact Us | 91 | 1 |
| Disclaimer | 92 | 1 |